<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<base href="Senate%203/24/25%202R">
<title>A4163 2R</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:AlbertusExtraBold;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	letter-spacing:.2pt;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	letter-spacing:.2pt;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuReprint>[Second Reprint]</p>

<p class=bpuBill>ASSEMBLY, No. 4163 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED APRIL 8, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman  SHAVONDA E. SUMTER</p>

<p class=bpuSponsor>District 35 (Bergen and Passaic)</p>

<p class=bpuSponsor>Assemblyman  GARY S. SCHAER</p>

<p class=bpuSponsor>District 36 (Bergen and Passaic)</p>

<p class=bpuSponsor>Assemblywoman  SHAMA A. HAIDER</p>

<p class=bpuSponsor>District 37 (Bergen)</p>

<p class=bpuSponsor>Senator  VIN GOPAL</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>Senator  TROY SINGLETON</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblywomen Bagolie, Hall, Donlon, Matsikoudis, Lopez,
Pintor Marin, Assemblymen Clifton, Sampson, Karabinchak, Assemblywoman Flynn,
Assemblymen DePhillips, Calabrese, Barlas, Assemblywoman Speight, Assemblymen
Spearman, DiMaio, Assemblywoman Peterpaul, Assemblymen McClellan, Simonsen,
Hutchison, Verrelli, Assemblywoman Park, Assemblyman Stanley, Assemblywoman
Reynolds-Jackson, Assemblymen Azzariti Jr., Inganamort, Auth, Assemblywoman
N.Munoz, Assemblyman Schnall, Assemblywomen Drulis, Dunn, Morales, Ramirez,
Assemblyman Rodriguez, Assemblywoman Swain, Assemblyman Tully, Senators
A.M.Bucco, Johnson, Greenstein, Pennacchio, Diegnan, McKnight, Beach,
Cruz-Perez, Zwicker, Bramnick, Burgess, Singer, Wimberly and O'Scanlon</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires health insurers to provide coverage for
biomarker precision medical<span style='letter-spacing:.2pt'> </span>testing.</p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As amended by the Senate on March 24, 2025.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:150%'><b><span
style='line-height:150%;font-variant:small-caps;letter-spacing:0pt'>An Act</span></b>
<span style='letter-spacing:0pt'>concerning health insurance coverage for
biomarker </span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>2</span></sup></b><u><span style='letter-spacing:0pt'>precision
medical</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>2</span></sup></b><span style='letter-spacing:0pt'> testing
</span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>1</span></sup></b><b><span style='font-family:"Albertus Extra Bold",sans-serif;
letter-spacing:0pt'>[</span></b><span style='letter-spacing:0pt'>and amending</span><b><span
style='font-family:"Albertus Extra Bold",sans-serif;letter-spacing:0pt'>]<sup>1</sup></span></b><span
style='letter-spacing:0pt'> and supplementing various parts of the statutory
law.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    a.  Each hospital
service corporation contract that provides hospital or medical expense benefits
and is delivered, issued, executed, or renewed in this State pursuant to
P.L.1938, c.366 (C.17:48-1 et seq.) or is approved for issuance or renewal in
this State by the Commissioner of Banking and Insurance, on or after the
effective date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.    ,
c.     (C.        ) (pending before the Legislature as this bill)<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing,
as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide treatment
decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a subscriber when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a subscribers disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or FDA-cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
hospital service corporation shall provide</u><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b> a decision <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
subscriber and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing
for the subscriber shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the
contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all hospital service corporation contracts in which the
hospital service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.<span style='font-size:11.5pt;line-height:150%'>  </span>The
guidelines establish standards of care informed by a systematic review of
evidence and an assessment of the benefits and risks of alternative care
options and include recommendations intended to optimize patient care.<span
style='font-size:11.5pt;line-height:150%'> </span><br clear=all
style='page-break-before:always'>
</p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  Each medical service
corporation contract that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1940,
c.74 (C.17:48A-1 et seq.) or is approved for issuance or renewal in this State
by the Commissioner of Banking and Insurance, on or after the effective date of
<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.    ,
c.     (C.        ) (pending before the Legislature as this bill)<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing,
as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a subscriber when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a subscribers disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
medical service corporation shall provide</u><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b> a decision <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
subscriber and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et. al)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing
for the subscriber shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the
contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all medical service corporation contracts in which the
medical service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>      1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</p>

<p class=MsoNormal style='line-height:150%'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  Each health service
corporation contract that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1985,
c.236 (C.17:48E-1 et seq.) or is approved for issuance or renewal in this State
by the Commissioner of Banking and Insurance, on or after the effective date of
<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the
Legislature as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a subscriber when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a subscribers disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:           </p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a subscriber.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
health service corporation shall provide</u><b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b> a decision <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
subscriber and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The subscriber and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the subscriber shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the
contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health service corporation contracts in which the
health service corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing
means the analysis of tissue, blood, or other biospecimen for the presence of a
biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    a.  Each individual
health insurance policy that provides hospital or medical expense benefits and
is delivered, issued, executed, or renewed in this State pursuant to chapter 26
of Title 17B of the New Jersey Statutes or is approved for issuance or renewal
in this State by the Commissioner of Banking and Insurance, on or after the
effective date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the
Legislature as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing,
as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2 </span></sup></b>testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of an insured when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for an insureds disease or condition is recognized
by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an insured.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
carrier shall provide</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
a decision <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
insured and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The insured and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the insured shall have access to clear, readily accessible, and conspicuous
information on the process to submit an appeal to an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the
contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</p>

<p class=MsoNormal style='line-height:150%'><span style='font-size:11.5pt;
line-height:150%'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'>     5.    a. &nbsp;Each group
health insurance policy that provides hospital or medical expense benefits and
is delivered, issued, executed, or renewed in this State pursuant to chapter 27
of Title 17B of the New Jersey Statutes or is approved for issuance or renewal
in this State by the Commissioner of Banking and Insurance, on or after the
effective date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the
Legislature as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide benefits for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of an insured when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for an insureds disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an insured.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>an
insurer shall provide</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
a decision <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
insured and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The insured and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the insured shall have access to clear, readily accessible, and conspicuous
information on the process to submit an appeal to an adverse determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the
contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with copayment,
deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all policies in which the insurer has reserved the right
to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the presence
of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span><br
clear=all style='page-break-before:always'>
</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  Each individual
health benefits plan that provides hospital or medical expense benefits and is
delivered, issued, executed, or renewed in this State pursuant to P.L.1992,
c.161 (C.17B:27A-2 et seq.) or is approved for issuance or renewal in this
State by the Commissioner of Banking and Insurance, on or after the effective
date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.    (C.        ) (pending before the Legislature as this
bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide benefits for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection g. of this section.&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker  <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a covered person when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a covered persons disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
carrier shall provide</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
a decision <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
covered person and the appropriate health care provider, and if the request is
made through a health care entity, to the health care entity, within 72 hours
for a non-urgent request or 24 hours for an urgent request<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The covered person and
the treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the covered person shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the health
benefits plan<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    a. &nbsp;Each small
employer health benefits plan that provides hospital or medical expense
benefits and is delivered, issued, executed, or renewed in this State pursuant
to P.L.1992, c.162 (C.17B:27A-17 et seq.) or is approved for issuance or
renewal in this State by the Commissioner of Banking and Insurance, on or after
the effective date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the
Legislature as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide benefits for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection g. of this section.&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a covered person when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a covered persons disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b> utilization
review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
carrier shall provide</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
a decision <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
covered person and the appropriate health care provider, and if the request is
made through a health care entity, to the health care entity, within 72 hours
for a non-urgent request or 24 hours for an urgent request<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant
to the guidelines and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et
al.)</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The covered person and
the treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the covered person shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The benefits shall be
provided to the same extent as for any other medical condition under the health
benefits plan<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to all health benefits plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.      a. &nbsp;Each health
maintenance organization contract for health care services that is delivered,
issued, executed, or renewed in this State pursuant to P.L.1973, c.337 (C.26:2J-1&nbsp;et&nbsp;seq.)&nbsp;or
is approved for issuance or renewal in this State by the Commissioner of
Banking and Insurance, on or after the effective date of <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>, shall
provide health care services for biomarker <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span style='letter-spacing:
0pt'>precision medical</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection g. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of an enrollee when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for an enrollees disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
an enrollee.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><u>a
health maintenance organization shall provide</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b> a
decision <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>shall be
rendered on a prior authorization request, and notice shall be sent to the
enrollee and the appropriate health care provider, and if the request is made
through a health care entity, to the health care entity, within 72 hours for a
non-urgent request or 24 hours for an urgent request<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>pursuant to the guidelines
and timeframes set forth in P.L.2023, c.296 (C.17B:30-55.1 et al.)</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The enrollee and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the enrollee shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The health care
services shall be provided to the same extent as for any other medical
condition under the contract<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, including determinations of clinical review
criteria used for utilization review of health care services along with
copayment, deductible, and coinsurance provisions</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     f.     The provisions of this
section shall apply to those contracts for health care services by health
maintenance organizations under which the right to change the schedule of
charges for enrollee coverage is reserved.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     9.      a. &nbsp;The State
Health Benefits Commission shall ensure that every contract providing hospital
or medical expense benefits, which is purchased by the commission on or after
the effective date of <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>P.L.
&nbsp;&nbsp;&nbsp;, c.&nbsp; &nbsp; (C.        ) (pending before the Legislature
as this bill)<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>,
provides coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection e. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a covered person when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a covered persons disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits
disruption, including multiple biopsies or biospecimen samples, in the care of
a covered person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, a decision shall be rendered <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>on a prior
authorization request, and notice shall be sent to the covered person and the
appropriate health care provider, and if the request is made through a health
care entity, to the health care entity, within 72 hours for a non-urgent
request or 24 hours for an urgent request<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>pursuant to the guidelines and timeframes set forth in P.L.2023, c.296
(C.17B:30-55.1 et al.)</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The covered person and
the treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
to the covered person shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     As used in this
section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a
specific therapeutic intervention, including known gene-drug interactions for
medications being considered for use or already being administered. Biomarkers
shall also include, but not be limited to, gene mutations, characteristics of
genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.</p>

<p class=MsoNormal style='line-height:150%'><span style='font-size:11.5pt;
line-height:150%'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'>     10.    a. &nbsp;The School
Employees Health Benefits Commission shall ensure that every contract
providing hospital or medical expense benefits, which is purchased by the
commission on or after the effective date of <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>P.L. &nbsp;&nbsp;&nbsp;, c.
&nbsp;&nbsp; (C.        ) (pending before the Legislature as this bill)<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>this act</u></span><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>,
provides coverage for biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing, as defined by subsection e. of this section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of a covered person when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for a covered persons disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits disruption,
including multiple biopsies or biospecimen samples, in the care of a covered
person.</p>

<p class=MsoNormal style='line-height:150%'>     d.    (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, a decision shall be rendered <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>on a prior
authorization request, and notice shall be sent to the covered person and the
appropriate health care provider, and if the request is made through a health
care entity, to the health care entity, within 72 hours for a non-urgent
request or 24 hours for an urgent request<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>pursuant to the guidelines and timeframes set forth in P.L.2023, c.296
(C.17B:30-55.1 et al.)</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The covered person and
the treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the covered person shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     e.     As used in this
section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>     <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Consensus
statement means a statement developed by an independent, multidisciplinary
panel of experts utilizing a transparent methodology and reporting structure
and with a conflict of interest policy.  The statement shall be aimed at
specific clinical circumstances and be based on the best available evidence for
the purpose of optimizing the outcomes of clinical care.<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>1</sup></span></b></p>

<p class=MsoNormal style='line-height:150%'>     Nationally-recognized
clinical practice guidelines means evidence-based clinical practice guidelines
developed by independent organizations or medical professional societies
utilizing a transparent methodology and reporting structure and with a conflict
of interest policy.  The guidelines establish standards of care informed by a
systematic review of evidence and an assessment of the benefits and risks of
alternative care options and include recommendations intended to optimize
patient care.<span style='font-size:11.5pt;line-height:150%'> </span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     11.  a.  Notwithstanding any
State law or regulation to the contrary, the Department of Human Services shall
ensure that expenses incurred for biomarker <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span style='letter-spacing:
0pt'>precision medical</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing shall be provided with no cost-sharing to persons served under the
Medicaid program, established pursuant to P.L.1968, c.413
(C.30:4D-1&nbsp;et&nbsp;seq.).</p>

<p class=MsoNormal style='line-height:150%'>     b.    Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
shall be covered for the purposes of diagnosis, treatment, appropriate
management, or ongoing monitoring of a disease or condition<b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>, excluding asymptomatic screening, to guide
treatment decisions</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
of an individual when the <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>test is
supported by medical and scientific evidence, including, but not limited to<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b><span
style='letter-spacing:0pt'> <u>efficacy and appropriateness of biomarker
precision medical testing for the diagnosis, treatment, appropriate management,
or guiding treatment decisions for an individuals disease or condition is
recognized by</u></span><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   labeled indications for
an FDA-approved or -cleared test; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   indicated tests for an
FDA-approved drug; </p>

<p class=MsoNormal style='line-height:150%'>     (3)   <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>actions to address</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><span
style='letter-spacing:0pt'> </span>warnings and precautions on FDA-approved
drug labels;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Centers for Medicare and
Medicaid Services National Coverage Determinations or Medicare Administrative
Contractor Local Coverage Determinations; or</p>

<p class=MsoNormal style='line-height:150%'>     (5)   nationally-recognized
clinical practice guidelines <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and consensus
statements<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]<sup>2</sup></span></b>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Coverage, pursuant to
subsection b. of this section, shall be provided in a manner that limits disruption,
including multiple biopsies or biospecimen samples, in the care of an
individual.</p>

<p class=MsoNormal style='line-height:150%'>     d.    If the Division of
Medical Assistance and Health Services in the Department of Human Services
contracts with a third-party entity to deliver biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
services pursuant to this section to beneficiaries under the Medicaid program,
the third-party entity shall provide biomarker <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span style='letter-spacing:
0pt'>precision medical</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing at the same scope, duration and frequency as the Medicaid program
otherwise provides to individuals.</p>

<p class=MsoNormal style='line-height:150%'>     e.     (1)        <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Notwithstanding
any other law, rule, or regulation to the contrary, if<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>If</u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>
utilization review is required, a decision <b><sup><span style='font-family:
"Albertus Extra Bold",sans-serif'>1</span></sup></b><b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>shall be rendered on a prior
authorization request, and notice be sent to an individual, the appropriate
health care provider, and, if necessary, the requisite health care entity if
the request for prior authorization was submitted through the entity, within 72
hours for a non-urgent request or 24 hours for an urgent request<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>shall be
provided pursuant to the guidelines and timeframes set forth in P.L.2023, c.296
(C.17B:30-55.1 et al.)</u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>1</span></sup></b>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The individual and the
treating health care provider or treating health care entity prescribing
biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
for the individual shall have access to clear, readily accessible, and
conspicuous information on the process to submit an appeal to an adverse
determination.</p>

<p class=MsoNormal style='line-height:150%'>     f.     As used in this
section:</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker means a
characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses
to a specific therapeutic intervention, including known gene-drug interactions
for medications being considered for use or already being administered.
Biomarkers shall also include, but not be limited to, gene mutations,
characteristics of genes, or protein expression.</p>

<p class=MsoNormal style='line-height:150%'>     Biomarker <b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
testing means the analysis of tissue, blood, or other biospecimen for the
presence of a biomarker.  Biomarker <b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>precision medical</span></u><b><sup><span
style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b> testing
includes<b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b><u><span
style='letter-spacing:0pt'>,</span></u><b><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>2</span></sup></b>
but is not limited to, single-analyte tests, multiplex panel tests, protein
expression, and whole exome, whole genome, and whole transcriptome sequencing.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     12.  This act shall take
effect on the 90th day next following enactment and shall apply to policies and
contracts issued or renewed on or after the effective date.</p>

</div>

</body>

</html>
